AbbVie Presents Optimistic Take For 2020, Expects Quick Recovery For Botox Aesthetic
Executive Summary
AbbVie made only a slight adjustment to its earnings-per-share guidance despite expected Q2 downturn due to the pandemic. It sees Allergan’s aesthetic business as bouncing back quickly.
You may also be interested in...
AbbVie Says Botox Business Recovering But Allergan Drags Down Q2 Financials
AbbVie reported revenue growth during the second quarter, with products like Rinvoq and Skyrizi leading the charge. But Allergan, despite growth for Vraylar and Ubrelvy, pushed down overall performance.
AbbVie’s Rinvoq Shines In First Of Three Eczema Pivotal Studies
The JAK1 inhibitor showed skin clearance and itch reduction in first of three Phase III trials. Analysts say blockbuster atopic dermatitis indication is possible if data hold up in ongoing studies.
AbbVie Pays $60m To Option Alpine’s Lupus Candidate
Deal Snapshot: Set to begin a Phase II study that Alpine will complete, ALPN-101 is a dual inhibitor of CD28 and ICOS that may offer a new treatment option in SLE.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports